Introduction
Over the past decades several female-specific risk factors have been identified indicating an elevated future cardiovascular disease (CVD) risk. These can be related to hormonal status such as early/late menarche, menstrual irregularities, polycystic ovary syndrome, endometriosis and early natural or surgical menopause. 1 Most important risk factors, however, are related to pregnancy disorders, such as recurrent miscarriages, gestational diabetes and hypertensive pregnancy disorders (HPDs) with preeclampsia/HELLP as the most severe manifestations. 2 It is unclear yet to what extent and within which stage(s) of life these female-specific risk factors are relevant to CVD risk estimation in women. When considering all agegroups together, reproductive and pregnancy related disorders do not seem to affect 10 years risk estimation. 3 For younger women (<60 years), however, who are often considered to be at low risk, there is now overwhelming evidence that a previous history of preeclampsia is a major tool in identifying elevated and premature CVD risk. This has resulted in the addition of preeclampsia/HELLP as a female-specific risk factor in several guidelines, such as the 2014 American Heart Association stroke prevention guideline and the 2016 European Society of Cardiology guideline CVD prevention. 4, 5 It remains to be determined how this risk should be weighed against the well known lifestyle and traditional risk factors and at what moment in time which preventive measures should be taken. Moreover, less severe and more heterogeneous expressions of HPD, occurring in 10-15% of all pregnancies, are 4-5 times more common than preeclampsia, and follow-up measures after HPDs have not been clearly defined.
In this journal a systematic review by Groenhof et al. is published in which the appearance of CVD risk factors in female populations is evaluated in the first two decades after HPD. 6 In 6904 women from 44 studies, levels of blood pressure (BP), glucose and lipids were evaluated and compared with those of age-matched women within three different healthy reference cohorts. It was found that 20% of women after HPD had hypertension around the age of 45 years, on average 15 years post index pregnancy. No differences were found in glucose and lipid levels between affected women and women in the reference cohorts. It should be noted, however, that most of these women were still premenopausal, which may have favourably affected these metabolic and lipid parameters. The authors express their uncertainty of how to optimally manage prevention after HPD, whereas the rapid developing field of eHealth applications may be an obvious solution for this relatively young at risk patient group.
Severity of HPD is leading
Hypertension is the major and key risk factor appearing in the first two decades after HPD, being present in 20% of women in their mid-40s. Women who have had early preeclampsia, however, are more prone to an earlier onset of hypertension, with more than 40% having an elevated BP before the age of 40. 7 The severity of the previous HPD is apparently an important determinant of the moment in life when premature hypertension begins. 8 Prevention strategies should therefore be stratified according to the severity and gestational age of the index HPD. This can be easily captured in patient records by gynaecologists and communicated to patients and their doctors. Moreover, a low birth weight, which most women are able to recall later in life, is an important and reliable indication for the severity of the HPD and thus may be a helpful tool in clinical practice.
Arterial placental insufficiency may be caused by genetic, immunological, vascular and environmental factors and has many pathophysiological mechanisms in common with the initial process of atherosclerosis. 9 The release of inflammatory stimuli leads to a persistently enhanced vascular response to injury post-pregnancy causing endothelial dysfunction and vasoconstriction. For the best approach in women post-pregnancy it may be important to consider the severest forms of HPD, especially early preeclampsia/ HELLP, as the first manifestations of a CVD event. These are the women who often remain symptomatic afterwards with complaints of fatigue, concentration disturbances, headaches, recurrent atypical chest pain, palpitations and impaired mental well-being. 1 This significantly interferes with their duties in a young family and at work. They may have persistent hypertension and premature (subclinical) manifestations of CVD for which the guidelines for secondary prevention are more suitable than those for primary prevention. This category of patients should be controlled at regular intervals (1-2 times per year) by a physician or well trained nurse. To implement this in clinical practice, though, a wider knowledge than currently exists is urgently needed among healthcare providers. 10 
Promote self monitoring of blood pressure
For the majority of women after HPD it is as yet unclear how BP should be optimally monitored. Healthy women leading busy lives are not likely to seek medical attention to check their BP regularly and they do not want to be considered as lifelong 'patients' either. Elevated BP may therefore remain undetected and un(der)treated for (many) years, leading to premature end-organ damage. Self-measurement of BP may be more effective and feasible for prospective follow-up in these relatively young women than incidental BP measurements at a physician's office. The use of modern eHealth applications to monitor BP at home intensifies patient involvement and increases motivation for healthy lifestyle adherence and better intake of prescribed medication. 11 This needs to be further explored in this potentially very suitable patient group.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
